<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454103</url>
  </required_header>
  <id_info>
    <org_study_id>Wue_123IMTO_100/05</org_study_id>
    <nct_id>NCT00454103</nct_id>
  </id_info>
  <brief_title>Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wuerzburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The improvement of conventional imaging techniques has led to an increased detection rate of&#xD;
      different adrenal tumors. Since those tumors can belong to a variety of entities the&#xD;
      therapeutic consequences also show considerable variation. In order to definitely determine&#xD;
      the type of tumor, invasive procedures like CT guided biopsies are often required, which&#xD;
      could be avoided by a tumor specific imaging method. The presently available scintigraphic&#xD;
      procedures are either time consuming and lead to high radiation exposure or are technically&#xD;
      demanding. The steroidogenic enzymes CYP11B1 (11ß-hydroxylase)and CYP11B2 (aldosterone&#xD;
      synthase)are expressed exclusively in the adrenal cortex and therefore represent suitable&#xD;
      targets for a specific imaging technique. In our project we evaluate 123I-Iodometomidate&#xD;
      which binds to both CYP11B enzymes as radiotracer for adrenal scintigraphy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Adrenal Tumor</condition>
  <condition>Adrenocortical Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>123I-Iodometomidate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adrenal tumor seen by CT or MRT-scan with diameter of at least 2 cm or patient with&#xD;
             adrenocortical carcinoma and suspected metastasis or local recurrence or patients with&#xD;
             primary hyperaldosteronismus and adrenal tumour &gt; 1 cm&#xD;
&#xD;
          2. Hormonal work up of of the adrenal tumor according to ENS@T (European network for the&#xD;
             study of adrenal tumours)-criteria&#xD;
&#xD;
          3. Age ≥ 30 Jahre&#xD;
&#xD;
          4. Effective contraception (pearl index &lt;1%)&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breast feeding&#xD;
&#xD;
          2. Renal insufficiency (serum creatinine &gt; 2,0 mg/dl or MDRD &lt; 60 ml/min)&#xD;
&#xD;
          3. Known allergy to etomidate or constituents of the test drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Reiners, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wuerzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2010</last_update_posted>
  <keyword>adrenocortical carcinoma (ACC)</keyword>
  <keyword>adrenal tumor</keyword>
  <keyword>metastastic adrenocortical carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

